Introduction
============

Hereditary nonpolyposis colorectal cancer (HNPCC) is the most common form of hereditary colorectal cancer, comprising 3%-4% of colorectal cancer cases \[[@b1-crt-2014-288]\]. The lifetime risk of colorectal cancer (CRC) in these patients is as high as 80%, and HNPCC is associated with extra-colonic tumors of endometrium, ovary, urinary tract, small intestine, stomach, brain, and sebaceous glands \[[@b1-crt-2014-288]\]. Although HNPCC was formerly used as a synonym for Lynch syndrome, HNPCC can encompass a heterogeneous group of hereditary nonpolyposis CRCs with or without germline mutations of mismatch repair (MMR) genes. Clinically diagnosed HNPCC by the Amsterdam criteria can include not only Lynch syndrome but also Lynch-like syndrome or familial CRC type X \[[@b2-crt-2014-288],[@b3-crt-2014-288]\]. In recognition of this problem, the latest World Health Organization (WHO) classification of tumors of the digestive system recommended "Lynch syndrome" as the standard term of a hereditary cancer syndrome caused by a germline mutation in one of the MMR genes \[[@b4-crt-2014-288]\]. Lynch syndrome is caused by germline mutations in MMR genes, including *MLH1*, *MSH2*, *MSH6*, and *PMS2* \[[@b5-crt-2014-288]\]. Early identification of such mutation carriers is essential to facilitate counseling, intensive surveillance and prophylactic surgery or chemoprevention. Since universal genetic testing is not cost-effective considering the rarity of this condition and germline sequencing efforts, it is necessary to prescreen individuals with suspected Lynch syndrome prior to genetic testing \[[@b6-crt-2014-288]\].

Several clinical criteria and molecular tests are used to screen individuals with MMR mutations. However, strategies for identifying MMR mutation carriers require improvement. Amsterdam criteria I and II, originally developed to define families suspected of HNPCC \[[@b7-crt-2014-288]\], are commonly utilized to determine eligibility for testing. However, these criteria are too stringent for use as a screening tool, leading to lack of sensitivity and specificity \[[@b6-crt-2014-288]\]. The less strict Bethesda guidelines have been utilized for this purpose \[[@b8-crt-2014-288]\], but may also overlook up to 15% of mutation carriers \[[@b9-crt-2014-288]\]. Another available method to detect possible Lynch syndrome families is microsatellite instability (MSI) testing, the genetic hallmark of Lynch syndrome. However, about 15% of sporadic CRC patients exhibit MSI \[[@b10-crt-2014-288]\], which may result in unnecessary genetic evaluation. Immunohistochemical analysis (IHC) of the major MMR proteins, MLH1 and MSH2, is used to identify individuals with MMR mutations. However, given that up to 5% of patients with Lynch syndrome show microsatellite stable or normal IHC staining \[[@b11-crt-2014-288]\], those at high risk of MMR mutations may be undetected. The most critical shortcoming of these clinical criteria and molecular testing protocols is that they are not designed to determine the risk of MMR mutations in individuals \[[@b6-crt-2014-288]\].

Several prediction models to help assess the probability of MMR mutations in individuals have been developed \[[@b12-crt-2014-288]-[@b14-crt-2014-288]\]. The prediction tools, MMRPredict \[[@b12-crt-2014-288]\], PREMM~1,2,6~ \[[@b14-crt-2014-288]\], and MMRPro \[[@b13-crt-2014-288]\], are widely used to estimate the likelihood of harboring MMR gene mutations based on clinical information. A number of Western population-based studies have validated the feasibility of these models \[[@b6-crt-2014-288],[@b11-crt-2014-288],[@b15-crt-2014-288]-[@b19-crt-2014-288]\] in facilitating potential advancement in screening and diagnosis of Lynch syndrome. Considering the ethnic differences of Lynch syndrome patients evaluated previously \[[@b20-crt-2014-288]-[@b22-crt-2014-288]\], prediction models need to be validated before clinical application in Asian countries. Therefore, the current study was designed to assess the performance of prediction models for MMR gene mutations in the Korean population.

Materials and Methods
=====================

We retrospectively obtained data from the Korean Hereditary Tumor Registry, including clinical and molecular findings from HNPCC or suspected HNPCC families. HNPCC and suspected HNPCC were defined according to Amsterdam criteria II \[[@b7-crt-2014-288]\] and revised S-HNPCC I criteria \[[@b23-crt-2014-288]\]. One hundred and eighty-eight individuals from 142 families with available details on pedigree and results of mutation screening for MMR genes were included in the study.

Mutational risk scores were calculated for the three prediction models, MMRPredict, PREMM~1,2,6~ and MMRPro.

MMRPredict, developed by Barnetson et al. \[[@b12-crt-2014-288]\], is a web-based online calculator freely available at <http://hnpccpredict.hgu.mrc.ac.uk/>. Variables in this model include proband age, sex, tumor location, presence of synchronous or metachronous CRC, presence and age of first-degree relatives with CRC or endometrial cancer. The model is limited to CRC-related patients only, since it was developed based on data from patients under the age of 55 diagnosed with CRC. Therefore, data for only 149 individuals were calculated for this model.

PREMM~1,2,6~ \[[@b14-crt-2014-288]\] is also freely available at [http://premm.dfci.harvard.edu/](http://hnpccpredict.hgu.mrc.ac.uk/). This model consists of proband-specific and family member-related variables, including occurrence and age at diagnosis of CRC, endometrial cancer, and other Lynch-associated tumors.

MMRPro is calculated with CaGENE 5.2 software (Cancer-Gene, Dallas, TX) available at <http://www4.utsouthwestern.edu/breasthealth/cagene>. This model includes age at diagnosis of CRC or endometrial cancer of the proband, first- and second-degree relatives and current age of unaffected relatives.

Missing or unknown data were imputed by applying a practice similar to previous studies \[[@b11-crt-2014-288],[@b17-crt-2014-288]\]. In unknown cases, age was estimated based on the age of relatives, assuming 30-year separation between generations. When only information about an individual's age group was available, a mid-range age was used \[[@b11-crt-2014-288]\]. Unknown tumor location was entered into the prediction model as both proximal and distal locations, and the mean value of the two was used \[[@b17-crt-2014-288]\].

Individuals were given mutational screening for the MMR genes---*MLH1*, *MSH2* and *MSH6*. Peripheral blood lymphocytes were isolated using Ficoll-Paque (Amersham Biosciences, Uppsala, Sweden), and genomic DNA was extracted using TRI reagent according to the manufacturer's instructions (Molecular Research Center, Cincinnati, OH). Next, we screened all gene coding regions, exon/intron boundaries and core promoters using polymerase chain reaction--single strand conformation polymorphism analysis to detect germline mutations in MMR genes. The detailed methods are described in a previous report by our group \[[@b20-crt-2014-288]\].

The expected frequency of MMR mutations was compared with observed frequency to test the reliability of the three models \[[@b24-crt-2014-288]\]. Receiver-operator characteristic (ROC) curves were constructed to evaluate precision. Area under the ROC curve (AUC) was calculated as a measure of discrimination for each model \[[@b24-crt-2014-288]\]. We additionally estimated specificity, positive likelihood ratios and predicted risk scores at a range of sensitivities (90%, 95%, and 98%) to test model accuracy \[[@b24-crt-2014-288]\]. Chi-squared test and Student's t test were employed to compare categorical and continuous data. We rejected null hypotheses of no difference if p-values were less than 0.05. Statistical analyses used SPSS ver. 19.0 (IBM Corp., Armonk, NY).

Results
=======

Of the 188 subjects, 57 were diagnosed as HNPCC, 44 were their family members, 85 were suspected HNPCC probands, and the remaining two were from a suspected HNPCC family. Clinical characteristics of patients are summarized in [Table 1](#t1-crt-2014-288){ref-type="table"}. Sixty-two (33.0%) carried MMR gene mutations, 77.8% of which were *MLH1*. The majority of mutations identified were frameshift (53.7%) or missense (38.9%) mutations. Individuals with MMR mutations were significantly younger (40.2±13.7 years) than those without the mutations (47.7±14.1 years). We identified 40 men (35.1%) and 19 women (31.1%) with mutations; the proportions of men and women with mutations did not differ significantly. No association was evident between MMR mutation and cancer location.

The distribution of risk scores calculated for each model is depicted in [Fig. 1](#f1-crt-2014-288){ref-type="fig"}. The three prediction models showed different distribution patterns. Risk scores of PREMM~1,2,6~ were positively skewed, i.e., concentrated in the lower range, while those of MMRPro were skewed to the left, being concentrated in the higher range. Median risk scores were 25.0% for MMRPredict, 14.2% for PREMM~1,2,6~, and 82.25% for MMRPro.

We compared the expected frequency of MMR mutations predicted by each model with observed frequency, with subjects divided into five groups by the calculated risk scores ([Table 2](#t2-crt-2014-288){ref-type="table"}). All three models underestimated the frequency of mutations in the \< 50% risk score group. However, the models commonly overestimated the possibility of MMR mutations in the ≥ 50% risk score group. In general, PREMM~1,2,6~ underestimated the mutational frequency, with an expected to observed mutation ratio of 0.8, while MMRPredict and MMRPro tended to overestimate the possibility of mutations (expected/observed mutation carriers, 1.3 and 1.7, respectively).

The results of ROC analysis for three models are presented in [Fig. 2](#f2-crt-2014-288){ref-type="fig"}. We observed an AUC of 0.709 (95% confidence interval \[CI\], 0.634 to 0.784) for PREMM~1,2,6~, 0.683 (95% CI, 0.592 to 0.773) for MMRPredict and 0.590 (95% CI, 0.493 to 0.688) for MMRPro. AUC from the PREMM~1,2,6~ model was the highest, although this difference was not statistically significant.

We additionally calculated specificity, positive likelihood ratio and risk score cutoff of the three prediction models in a range of sensitivities ([Table 3](#t3-crt-2014-288){ref-type="table"}). To achieve a sensitivity of 90%, a cutoff risk score of \> 6.0% led to specificity of 34.3% and positive likelihood ratio of 1.4 for MMRPredict. Specificity decreased to 3.9% to obtain a sensitivity of 95%. For PREMM~1,2,6~, to gain a sensitivity of 90%, a cutoff risk score of \> 7.4% provided specificity of 36.3% and positive likelihood ratio of 1.4, highest among the three models. Specificity remained 32.3% at a sensitivity of 95%. PREMM~1,2,6~ showed the highest specificity (25.8%) at a sensitivity of 98%.

Discussion
==========

To our knowledge, this is the first study to explore the performance of Lynch prediction models in an Asian population. All three models tended to underestimate the possibility of MMR mutation in low-risk individuals; but overestimated the possibility of mutation in high-risk individuals. AUCs of the three models were 0.709 for PREMM~1,2,6~, 0.683 for MMRPredict and 0.590 for MMRPro, signifying fair to poor discrimination. Within the range of acceptable sensitivity that reduces the number of missed mutant carriers (sensitivity \> 90%), PREMM~1,2,6~ showed higher specificity (36.3%) than the other two models (34.3% for MMRPredict, 21.2% for MMRPro).

After the development of each Lynch syndrome prediction model \[[@b12-crt-2014-288]-[@b14-crt-2014-288]\], a number of studies explored performance in Western populations \[[@b6-crt-2014-288],[@b11-crt-2014-288],[@b15-crt-2014-288]-[@b19-crt-2014-288]\]. Some investigations used clinic-based samples similar to our study \[[@b6-crt-2014-288],[@b11-crt-2014-288],[@b17-crt-2014-288],[@b18-crt-2014-288]\] and others were from population-based samples \[[@b15-crt-2014-288],[@b16-crt-2014-288]\] or both \[[@b19-crt-2014-288]\]. Win et al. \[[@b25-crt-2014-288]\] reviewed prediction models for MMR gene mutations and performed a meta-analysis of AUCs from reviewed studies. Pooled AUCs were 0.84 for PREMM, 0.81 for MMRPredict, and 0.80 for MMRPro, indicative of good performance. Although some authors report that the Lynch prediction models provide no better discrimination than the revised Bethesda guidelines \[[@b16-crt-2014-288],[@b18-crt-2014-288]\], they are generally considered a feasible strategy for further risk assessment and genetic testing \[[@b5-crt-2014-288]\].

However, our results indicate that the available prediction models are not broadly applicable to Asians, since the molecular characteristics of CRC between patients with distinct ethnic origins are substantially different. For instance, De Jesus-Monge et al. \[[@b22-crt-2014-288]\] reported wide variations (0.6%-47.1%) in negative MLH1 protein expression in CRC patients from different countries. Previously, we showed differences in MMR gene mutations in Korean HNPCC families \[[@b20-crt-2014-288]\] and a lower rate of MSI-high (5.5%) in Korean CRC patients than European ethnicities (10%-25%) but rates similar to Japanese patients (4.5%-5.9%) \[[@b21-crt-2014-288]\]. These ethnic differences may hinder the application of prediction models to Koreans, resulting in poor performance.

Each prediction model has distinct characteristics \[[@b11-crt-2014-288], [@b17-crt-2014-288],[@b25-crt-2014-288]\]. Thus, clinical utilization of the three models may vary for different situations. MMRPredict is a web-based easily accessible model, but it includes only individuals diagnosed with CRC \[[@b17-crt-2014-288]\]. It can be useful for patients with early-onset CRC \[[@b11-crt-2014-288]\]. PREMM~1,2,6~ does not take into account MSI/IHC test results but is ideal for families with HNPCC-related cancers \[[@b11-crt-2014-288],[@b17-crt-2014-288]\]. MMRPro needs a complete family history demanding a first-degree relative affected to estimate risk to proband \[[@b11-crt-2014-288],[@b17-crt-2014-288]\]. The model is useful when MSI/IHC test results are both negative \[[@b11-crt-2014-288]\]. In our study population, the three models showed differences in reliability, accuracy, and even distribution. Considering both AUC and specificity within acceptable sensitivity, PREMM~1,2,6~ may have slightly better performance in Asian populations, despite lower reliability.

Our study has some limitations. Initially, data were collected from our registry database comprising HNPCC or suspected HNPCC families determined by Amsterdam criteria II or revised S-HNPCC I criteria. The registry-based retrospective study design prevented us from utilizing revised Bethesda guidelines, and resulted in lack of MSI testing or immunohistochemistry for MMR proteins, producing a bias. Nevertheless, AUCs of our study (0.590-0.709) were significantly lower than those of clinic-based studies on Western populations (0.77-0.82) \[[@b25-crt-2014-288]\]. In addition, the proportion of *MLH1* mutations (77.8%) among all detected MMR mutations is higher than that of previous studies (25%-44%) \[[@b6-crt-2014-288],[@b11-crt-2014-288],[@b16-crt-2014-288]-[@b19-crt-2014-288]\], which could represent potential selection bias. However, a population-based study reported a surprisingly low proportion (5.6%) of *MLH1* mutations among all detected mutations \[[@b15-crt-2014-288]\], suggesting that an unusually high proportion of *MLH1* mutations might happen by chance. Another possibility is that individuals from 11 families in this study inherited a founder mutation (c.1757_1758insC) in the *MLH1* gene from a common ancestor \[[@b20-crt-2014-288]\]. Because validation of a prediction model performance is individual-based, and therefore depends mainly on the precise mutational analysis and detailed family history of each individual, it seems unlikely that our results are severely biased.

Owing to the retrospective design, we were confronted with difficulties with missing data. Although methods similar to previous studies were used \[[@b11-crt-2014-288],[@b17-crt-2014-288]\], we could not apply all models to all individuals due to missing values. Lastly, we did not examine mutations in *PMS2* and *EpCAM* genes in this study. However, current prediction models were developed to predict the possibility of having mutations only in the *MLH1*, *MSH2*, and *MSH6* genes, and mutations in *PMS2* and *EpCAM* genes were not taken into account. This is a limitation of current prediction models, although mutations in *PMS2* or *EpCAM* genes are very rare in Lynch syndrome. Therefore, we believe that the present study is of value despite the lack of *PMS2* or *EpCAM* mutational results.

Conclusion
==========

The overall performances of all three prediction models in our Korean population were poor compared to that in Western populations. We propose that a new prediction model is required for the Korean population to effectively detect MMR mutation carriers that reflects ethnic differences in genotype-phenotype associations.
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###### 

Clinical characteristics by mutation status

  Characteristic        Mutation positive^[a)](#tfn2-crt-2014-288){ref-type="table-fn"}^ (n=62)   Mutation negative (n=126)   p-value
  --------------------- ------------------------------------------------------------------------- --------------------------- ---------
  **Age (yr)**          40.2±13.7                                                                 47.7±14.1                   0.001
  **Sex**                                                                                                                     
   Male                 40 (35.1)                                                                 74 (64.9)                   0.599
   Female               19 (31.1)                                                                 42 (68.9)                   
  **Probands**                                                                                                                
   No                   23 (50.0)                                                                 23 (50.0)                   0.005
   Yes                  39 (27.5)                                                                 103 (72.5)                  
  **Cancer**                                                                                                                  
   No                   13 (38.2)                                                                 21 (61.8)                   0.518
   Yes                  47 (32.4)                                                                 98 (67.6)                   
  **Cancer location**                                                                                                         
   Proximal colon       17 (34.7)                                                                 32 (65.3)                   0.635
   Distal colon         21 (28.0)                                                                 54 (72.0)                   
   Entire colon         7 (36.8)                                                                  12 (63.2)                   
  **Mutation gene**                                                                                                           
   *hMLH1*              42 (77.8)                                                                 \-                          \-
   *hMSH2*              9 (16.7)                                                                  \-                          
   *hMSH6*              3 (5.6)                                                                   \-                          
  **Mutation type**                                                                                                           
   Frameshift           29 (53.7)                                                                 \-                          \-
   Missense             21 (38.9)                                                                 \-                          
   Splicing             4 (7.4)                                                                   \-                          

Values are presented as mean±standard deviation or number (%).

Mutation positive: individuals with a germline mutation of the mismatch repair gene.

###### 

Comparison of expected and observed frequency of DNA mismatch repair gene mutations

  Model          Predicted risk score (%)   No. of individuals   No. of mutation carriers               
  -------------- -------------------------- -------------------- -------------------------- ----------- -----
  MMRPredict     \< 10                      50                   1.9 (3.8)                  6 (12.0)    0.3
                 10-25                      24                   3.8 (15.7)                 7 (29.2)    0.5
                 25-50                      20                   7.4 (37.2)                 10 (50.0)   0.7
                 50-75                      14                   9.0 (64.0)                 6 (42.9)    1.5
                 75-100                     41                   37.4 (91.2)                18 (43.9)   2.1
                 Total                      149                  59.5 (39.9)                47 (31.5)   1.3
  PREMM~1,2,6~   \< 10                      75                   4.0 (5.4)                  13 (17.3)   0.3
                 10-25                      44                   7.2 (16.4)                 15 (34.1)   0.5
                 25-50                      29                   10.6 (36.5)                15 (51.7)   0.7
                 50-75                      21                   12.8 (60.7)                9 (42.9)    1.4
                 75-100                     16                   13.9 (86.6)                9 (56.3)    1.5
                 Total                      185                  48.4 (26.2)                61 (33.0)   0.8
  MMRPro         \< 10                      16                   0.63 (3.9)                 4 (25.0)    0.2
                 10-25                      5                    0.8 (16.1)                 1 (20.0)    0.8
                 25-50                      34                   14.9 (43.9)                15 (44.1)   1.0
                 50-75                      14                   8.1 (58.0)                 5 (35.7)    1.6
                 75-100                     71                   68.1 (96.0)                30 (42.3)   2.3
                 Total                      140                  92.6 (66.2)                55 (39.3)   1.7

Values are presented as number (%).

###### 

Testing characteristics of the three prediction models at sensitivities of 90%, 95%, and 98%

  Sensitivity (%)              MMRPredict   PREMM~1,2,6~   MMRPro
  ---------------------------- ------------ -------------- ---------
  \> 90% Sensitivity                                       
   Specificity (%)             34.3         36.3           21.2
   Positive likelihood ratio   1.4          1.4            1.2
   Risk score cutoff (%)       \> 6.0       \> 7.4         \> 31.5
  \> 95% Sensitivity                                       
   Specificity (%)             3.9          32.3           11.8
   Positive likelihood ratio   1.0          1.4            1.1
   Risk score cutoff (%)       \> 0.0       \> 6.3         \> 7.0
  \> 98% Sensitivity                                       
   Specificity (%)             3.9          25.8           4.7
   Positive likelihood ratio   1.0          1.3            1.0
   Risk score cutoff (%)       \> 0.0       \> 5.2         \> 1.5

[^1]: The abstract of this article was presented at the 46th Annual Meeting of the Korean Society of Coloproctology in Gyeongju, Korea on April 5, 2013.
